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Introduction
  Biosensors are self-contained devices 
able to provide chemical or biological 
information as a signal (typically, optical 
or electrical) generated by a transducer 
in intimate contact with a  biorecognition 
layer. (1) In electrochemical sensors, 
a change in the redox state of the 
biorecognition/analyte system related 
to the biorecognition event, produces 
a change in an electrochemical quan-
tity which can be monitored by 
classical electroanalytical techniques. 
Electrochemical systems can be 
miniaturized below the micrometer 
scale, using individual nanoelectrodes 
or ordered arrays or random ensembles 
of  nanoelectrodes (NEA and NEE, 
respectively). (2) In particular, the use 
of  NEAs and NEEs allows to overcome 
problems related to the requirement 
for high signal amplification and careful 
shielding of electrical noise which 
is required for measurements with 
individual nanoelectrodes. Signals 
given by  NEAs and NEEs are indeed 
the summation (weighed by diffusion 
effects) of the signals generated at 
each single nanoelectrode element; (3) 
a drawback is that NEAs and NEEs do 
not allow the extreme “nano-turization” 
degree achievable with individual 
nanoelectrodes, however they can be 
brought down to arrays of overall micro-
size, but made of nanometer sized single 
components (4).
  Among the others, NEEs prepared 
by controlled deposition of metal 
nanoelements using polycarbonate 
ultrafiltration membranes as template, 
are attractive and increasingly used, 
since their fabrication procedure is easy 
and accessible. (5) Electroless deposition 
of gold in polycarbonate templates for 
producing NEEs was introduced some 
years ago by Menon and Martin (3) and 
refined more recently in our laboratories. 
(6) Membranes with pore diameter 
from 10 nm to 10 µm are commercially 
available. The diameter of the pores in 
the template determines the diameter of 
the Au-nanodisk elements that make up 
the NEE while the density of the pores in 
the membrane determines the number 
of Au- disk nanoelectrodes per cm2 
and their average distance. A NEE is an 
assembly of a very large number of very 
small ultramicroelectrodes confined in a 
rather small space (108 electrodes/cm2). 
NEEs can exhibit distinct voltammetric 
response regimes depending on the 
scan rate or distance between the 
nanoelectrode elements. (3) The total 
overlap (TO) regime is operative when 
radial diffusion boundary layers at 
each nanoelectrode overlap (slow scan 
rates and/or small distance between 
nanoelectrodes); this is the diffusion 
regime commonly observed for NEEs 
fabricated from commercial track-etched 
membranes. Under these conditions, the 
signal obtained at a NEE (namely, the 
faradaic peak current) is proportional 
to the geometric area (Ageom; that is 
area of the nanodisc electrodes plus 
insulating membrane between them), 
while the background current (i.e. double 
layer charging current) depends on the 
active area (Aact; area of the metal 
nanoelectrode elements alone) (4). 
As a consequence of the high Ageom/
Aact  ratio, NEEs are characterized by 
detection limits 2-3 orders of magnitude 
lower than those achievable with regular 
electrodes of the same geometric area. 
(7,8) Some bioanalytical applications of 
arrays and ensembles of nanoelectrodes 
have been very recently reviewed. (2)
  In typical schemes used to obtain 
electro-chemical biosensors, a biorecog-
nition layer is directly immobilized on 
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Detection schemes and immobilization 
procedures
   The two detection strategies summarized 
in Fig. 1 were used. In approach A, shown 
in Fig. 1A, the target protein is directly 
immobilized on the polycarbonate and 
recognized and detected by a suitable 
primary antibody and then by a secondary 
antibody labelled with HRP.
   According to approach B, sketched in 
Fig. 1 B, A specific antibody is immobilized 
on the polycarbonate, thus capturing 
the protein of interest, which is finally 
detected via primary plus secondary 
labelled antibody.
 Single chain fragment variable (ScFv) 
antibodies were cloned in the vector 
pDAN5, purified from DH5α E. coli cells 
using a nickel affinity resin and diluted in 
bicarbonate buffer (14). A microvolume of 
0.5 µl of a 4 µM ScFv solution was spotted 
onto the NEE, then incubated for 4 hours 
at 4°C. Electrodes were then washed with 
PBST (Phosphate Buffer Saline, added 
with 0,2% v/v Tween 20), and incubated for 
10 minutes in NaBH4 to block remaining 
carboxylic groups. (15) 
  Then the NEE was incubated with an 
anti-SV5 antibody (in house purified, 
diluted 1:3000 in Phosphate Buffer Saline 
added with milk powder and Tween20 
(PBST-milk), kindly provided by Daniele 
Sblattero), and finally with an anti-
mouse-HRP secondary antibody (Dako 
Cytomation, diluted 1:10000 in PBST-
milk). Trastuzumab functionalised NEEs 
(T-NEE) were prepared by incubating on 
the NEE 2 μl of 0.5 μg/μl trastuzumab 
(Hercerptin®, Genentech, South San 
Francisco, CA) in carbonate buffer, for 2 
hours at 4°C. After washing with PBST, 10 
μl of four dilutions (1:1, 1:5, 1:10, 1:50) of 
a 10 μg/μl SKBR3 lysate were incubated 
with the T-NEE for 4 hours at 4°C; the 
monoclonal antibody CB-11, diluted 
1:5000 in PBST-milk, was used to detect 
bound Her2, together with an anti-mouse 
HRP-conjugated antibody. 
  NEEs used as negative control were not 
incubated with the cell lysate, but, right 
after the immobilization of trastuzumab 
they were incubated with the CB-11 
antibody and the secondary antibody.
Results and discussion
 Preliminary tests performed in 
homogeneous solutions (mediator, 
enzyme and substrate all dissolved in 
solution), showed that the best mediator 
suitable to shuttle electron from the Au-
nanoelectrodes of a NEE to HRP was 
the electrode surface and the signal 
is produced by exchange of electrons 
between this layer and the underlying 
electrode. However, in the case of 
miniaturized electrodes, such as in the 
case of nanoelectrodes, the amount 
of immobilized biomolecules can be 
too small to give signals exploitable for 
analytical purposes. In order to increase 
the electrode area available for the 
immobilization, the template membrane 
can be etched. (9-11) In this way, 2D 
ensembles of metal nanodisks turn into 
a 3D ensembles of nanowires. However, 
this causes the loss of the main analytical 
advantage of NEEs, that is improved 
signal-to-background current ratios. (11)
In a recent paper (12) we demonstrated 
the feasibility and the advantages 
of a different approach, that is the 
immobilization of the biorecognition 
element on the polycarbonate surrounding 
the nanodisk electrodes and not on the 
nanoelectrodes themselves. In such a 
design, transducer and biorecogniton 
layer are not overlapped, but integrated 
in strict proximity; since no increase in 
the Aact is required, voltammetric signals 
are produced at the highest signal/
background current ratio.
  In the present study we report on the use 
of these nanobiosensors to determine 
two target proteins. One is the single 
chain fragment variable (ScFV) protein 
chosen as a general model protein, 
the other is the HER2 receptor which 
represents a quite important target 
protein connected to the development 
of the so-called personalized therapies. 
The possibility to detect HER2 is indeed 
extremely important for the identification 
of cancer that can be treated successfully 
with Herceptin (Trastuzumab), a 
recombinant DNA-derived humanized 
murine monoclonal antibody directed 
against the extracellular domain of the 
HER2 receptor. 
Experimental section
Apparatus and materials 
    All electroanalytical measurements were 
carried out at room temperature (22±1°C) 
under a nitrogen atmosphere, using a 
three-electrode single-compartment cell 
equipped with a platinum coil counter 
electrode and an Ag/AgCl (KCl saturated) 
reference electrode. All potential values 
are referred to this reference electrode. 
A CH660A potentiostat controlled via 
PC by its own software was used for 
voltammetric measurements. All the used 
chemicals were reagent grade and utilized 
without further purification. Horseradish 
peroxidase, type VI, 298 Purpurogallin 
units/mg solid, was purchased from 
Sigma. Purified water was obtained using 
a Milli-Ro plus Milli-Q (Millipore) water 
purification system.
 NEEs were prepared by template 
gold electroless deposition (13), follo-
wing recently described updates in 
the procedure. (6,13) The templating 
membranes were polycarbonate track-
etched filter membranes (SPI-pore, 47 
mm filter diameter, 6 µm thickness) with a 
nominal pore diameter of 30 nm, average 
pore density 6 x 108 pore/cm2 and coated 
by the producer with the wetting agent 
polyvinylpyrrolidone. 
 A hole punched in insulating layer of 
plastics (Monokote  film by Topflite, 
that is polyethylene terephtalate film 
with a polyethylene layer which acts as 
heat activated adhesive) determined 
the Ageom value, typically 0.07 cm2. The 
value of Aact, estimated by SEM analysis, 
was 0.001 cm2. 
Figure 1. Schematic illustration of 
the two detection approaches used 
with NEEs: (A) the target protein is 
immobilized on the polycarbonate 
membrane, then it binds a primary 
antibody and secondary antibody 
with the enzyme label (EL); a soluble 
mediator (Med) shuttle electrons from 
the nanoelectrode to EL. (B) A primary 
antibody, specific for the target protein, 
is first immobilized on the membrane, in 
order to capture the target protein. The 
other components follow as in scheme A.
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methylene blue (MB) which is reduced 
reversibly at the NEE according to the 
following reaction: 
        
 12  MB + 2e + H+        LB  (1)
where LB is the leuco (reduced) form of MB.
In the presence of HRP and its substrate 
H
2
O
2
, MB shuttles electrons from the 
nanoelectrode    to the enzyme label being 
involved in f the following electrocatalytic 
cycle: 
     
                  (2)
 In order to test the efficiency of the 
detection scheme shown in Fig. 1a,  further 
tests were performed by immobilizing 
ScFv on the NEE surface.  The protein 
was then bound to anti-SV5 antibody plus 
anti-mouse-HRP secondary antibody. 
The tests were performed by adding 
increasing  concentration of H
2
O
2
, thus 
allowing one to determine also the best 
operative range for the concentration of 
the enzyme substrate. As shown in Fig. 
2, even at relatively low concentration of 
H
2
O
2
 (namely, 1.5 mM) the voltammetric 
patterns assumed the typical sigmoidal 
electrocatalytic shape (full line).
  These results confirmed the feasibility at 
NEE of the detection scheme 1A, at least 
when using protein samples (like the ScFv 
sample tested here) very rich in analyte.
Methylene blue signals (see broken line in 
Fig. 2) at the NEE functionalised with ScFv- 
anti-SV5-anti-mouse-HRP (see broken 
line in Fig. 3) did not show significant 
differences with the signal recorded 
at unmodified  NEEs, so indicating no 
inhibition by the immobilized proteins 
on the charge transfer at the surface 
of the gold nanoelectrodes. The above 
evidences support the feasibility at NEEs 
of the detection scheme 1a, at least when 
high concentration of the target protein 
are present in the sample, as in the ScFv 
case.
  However, to the goal of analysing 
with NEEs samples containing small 
concentration of the target protein, the 
development of capture arrays based 
on the scheme in Fig.1b appeared more 
suitable.
  To this aim, we tested as capture agent 
trastuzumab, which is a monoclonal 
humanized antibody used in the adjuvant 
therapy of breast cancer. (16) At first, 
preliminary immunoprecipitation assays 
were performed. As negative control, we 
immunoprecipitated our sample using 
an anti-PCNA (Proliferating cell nuclear 
antigen, Santa Cruz Biotechnology, CA) 
antibody, while as positive control, 70 μg of 
whole SKBR3 (17) lysate were loaded onto 
the gel. Western blot analysis performed 
after the immunoprecipitation, indicated 
the bands, at 185 kDa and 95 kDa, both 
due to the Her2 protein, were clearly 
visible, so confirming (18) the efficiency 
of trastuzumab as capture agent in vitro. 
This prompted us to undergo the study 
of trastuzumab functionalised NEEs. 
The tests were performed with NEEs 
functionalized with Trastuzumab (see 
experimental section). The mediator, 
namely 0.1 mM MB, and the substrate 
(1.5 mM H
2
O
2
) were added to the PBS 
electrolyte. The cyclic voltammetric 
patterns for the mediator MB at a NEE 
after the immobilization of trastuzumab, 
recorded in the absence and in the 
presence of cell lysate, but always without 
HER2, overlap each other. This confirms 
that no change in the voltammetric 
behaviour of MB at the NEE is caused 
by functionalization with trastuzumab. 
Moreover, no aspecific adsorption of 
the labeled antibody occurs if the target 
protein (HER2) is not present in the 
sample.
  On the other hand, a significant 
increment in the current intensity (µI) 
was observed after incubation in the cell 
lysates, containing the target protein 
HER2, followed by incubation with 
the primary antibody and secondary 
antibody with the HRP label. Some tests 
were performed by changing the HER2 
concentration in the sample by proper 
dilution of a cell lysate (2 ng/µl before 
dilution) standardized by Western blot 
analysis, with a HER2 content of 1 µg/
µl, before dilution. The content of total 
proteins in the same undiluted sample 
was 10 µg/µl. The immobilization of the 
all four-proteins chain (specific antibody, 
target protein, primary antibody and 
secondary labeled antibody) hinders 
slightly, but do not block the electron 
transfer from the Au-nanoelectrodes 
to the mediator. This suggests that the 
protein chain is immobilized in very close 
proximity to the gold nanodisks, but not 
directly on them. The voltammogram 
recorded in the presence of 1.5 mM H
2
O
2 
shows a typical electrocatalytic character, 
with electrocatalytic µI values which 
increase with the HER2 concentration as 
shown in Fig. 3. The concentration of H
2
O
2
 
here used corresponds to the value which 
gives the highest electrocatlytic increase 
in peak currents, without causing an 
undesired increase in background current, 
as observed by us for instance when 3 or 5 
mM H
2
O
2
 was added to the sample. 
 Note that the sensitivity of classical 
immunochemical assays, such as Western 
blotting, is not high enough to detect 
the HER2 analyte at the dilution levels 
of our 1:10 or 1:50 samples, while good 
electrocatalytic signals were detected 
with the NEE in these diluted samples.
Preliminary tests on lysates of cancer cells 
overexpressing HER2 were successful 
and encouraging for the application of 
the NEE based biosensor to analyses of 
clinical samples. (12)
Figure 3. Dependence of electrocatalytic 
current increase (<I) on HER2 concen-
tration at a NEE functionalized with 
trastuzumab.  Cell lysates con-taining the 
target protein were diluted 1:10 (full line) 
and 1:50 (dashed line).
Fig.  2. Cyclic voltammograms 
recorded at a NEE functionalised 
with the target protein ScFv, the 
primary anti-SV5 antibody and 
the anti-mouse-HRP secondary 
antibody;  in solution containing  
0.1 mM methylene blue before 
(dash line) and after adding 1.5 
mM H
2
O
2
 (full line). Scan rate: 50 
mV/s, supporting electrolyte 10 mM 
phosphate buffer, pH 7.
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Conclusions
 The results presented here confirm 
the potentiality of electrochemical 
nanobiosensors based on ensembles of 
nanoelectrodes for the sensitive deter-
mination of target proteins, since with 
NEEs it was possible to detect target 
proteins in rather diluted samples (at 
least down to 20 pg/µl), where traditional, 
immunochemical method, such as Western 
blotting, failed for lack of sensitivity. 
Further studies aimed to validate the 
analytical performances of the sensor in 
terms of detection limit, dynamic range, 
accuracy and precision, are in progress. 
In combination with the possibility to 
prepare singly addressable groups of 
NEEs, (19) the present approach can open 
new prospects towards the development 
of miniaturized arrays of nanolectrodes, 
for multi-protein determinations.
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